Corinne Jenkins
Stock Analyst at Goldman Sachs
(2.28)
# 2,572
Out of 4,711 analysts
67
Total ratings
45.45%
Success rate
-2.03%
Average return
Main Sectors:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $56.12 | +17.61% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $32.20 | -31.68% | 8 | Nov 5, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $77 → $74 | $83.45 | -11.32% | 5 | Aug 8, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $4.35 | +244.83% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $25.61 | +79.62% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.57 | +55.57% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $3.49 | +43.27% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $8.25 | +57.58% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $34.28 | -18.32% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $35.59 | +46.11% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $4 | $0.34 | +1,073.02% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $0.83 | +2,686.53% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.72 | +672.06% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $5.86 | +138.91% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $15.52 | -48.45% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.58 | +2,677.78% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $56.12
Upside: +17.61%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $32.20
Upside: -31.68%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $77 → $74
Current: $83.45
Upside: -11.32%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $4.35
Upside: +244.83%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $25.61
Upside: +79.62%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.57
Upside: +55.57%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $3.49
Upside: +43.27%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $8.25
Upside: +57.58%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $34.28
Upside: -18.32%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $35.59
Upside: +46.11%
Aug 15, 2023
Maintains: Neutral
Price Target: $12 → $4
Current: $0.34
Upside: +1,073.02%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $0.83
Upside: +2,686.53%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.72
Upside: +672.06%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $5.86
Upside: +138.91%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $15.52
Upside: -48.45%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.58
Upside: +2,677.78%